Khorana, Alok A.
McCrae, Keith R.
Milentijevic, Dejan
Fortier, Jonathan
Nelson, Winnie W.
Laliberté, François
Crivera, Concetta
Lefebvre, Patrick
Schein, Jeff
Article History
Received: 30 August 2018
Accepted: 16 January 2019
First Online: 8 February 2019
Compliance with ethical standards
:
: Alok A. Khorana reports personal fees and non-financial support from JSA during the conduct of the study; plus personal fees and non-financial support from Bayer, Sanofi, Parexel, Halozyme, Pfizer, Seattle Genetics, AngioDynamics, Leo Pharma, and Medscape/WebMD; personal fees from Pharmacyclics, Pharmacyte, and TriSalus; grants from Merck, Array, Bristol-Myers Squibb, Leap Pharma, Porter Family Fund, National Heart, Lung and Blood Institute; and other from Sondra and Stephen Hardis Chair In Oncoology Research outside the submitted work. Keith R. McCrae has received research grants from JSA. François Laliberté and Patrick Lefebvre are employees of Groupe d’analyse, Ltée, a consulting company that has received research grants from JSA. Jonathan Fortier was an employee of Groupe d’analyse at the time this study was conducted. Dejan Milentijevic and Concetta Crivera are employees of JSA. Jeff Schein and Winnie W. Nelson were employees of JSA at the time this study was conducted.
: Data were de-identified and complied with the patient confidentiality requirements of the Health Insurance Portability and Accountability Act of 1996 (HIPAA). As this study used only anonymized data from a claims database, institutional review was not required.
: Informed consent was not required since the study used anonymized data.